Načítá se...
Novel targeted therapies of T cell lymphomas
T cell lymphomas (TCL) comprise a heterogeneous group of non-Hodgkin lymphomas (NHL) that often present at an advanced stage at the time of diagnosis and that most commonly have an aggressive clinical course. Treatment in the front-line setting is most often cyclophosphamide, doxorubicin, vincristin...
Uloženo v:
| Vydáno v: | J Hematol Oncol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7775630/ https://ncbi.nlm.nih.gov/pubmed/33384022 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-01006-w |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|